Research Overview
Across the provided abstracts, citicoline (CDP-choline) has been most studied in three domains: (1) neuro-ophthalmology/neuroprotection in glaucoma (with objective electrophysiologic outcomes such as pattern electroretinogram and visual evoked potentials), (2) cognition and age-related memory inefficiency in older adults without dementia (randomized, placebo-controlled designs assessing verbal and free-recall memory), and (3) substance-use–related outcomes in cocaine dependence (including comorbid bipolar disorder), with endpoints spanning memory performance, urine toxicology, craving/self-report measures, and, in one study, fMRI responses to food cues and appetite ratings. Doses and regimens vary substantially across studies (e.g., ~300–2000 mg/day orally; intramuscular 1000 mg/day in glaucoma), and several studies are explicitly described as preliminary or proof-of-concept with modest sample sizes.
The strongest evidence in these abstracts supports modest cognitive benefits in older adults with relatively inefficient baseline memory, particularly for verbal memory and free-recall measures, with effects more apparent at higher doses and in those with poorer initial performance. In glaucoma, repeated treatment periods were associated with improvements in objective measures of retinal function and visual pathway conduction, with partial regression during washout and longer-term treatment reported to stabilize or improve visual dysfunction—findings consistent with treatment-dependent neurofunctional effects, though the evidentiary strength depends on study design details not fully specified in the abstract. For cocaine dependence, results are mixed: one randomized add-on trial in bipolar disorder with cocaine dependence reported improvements in a declarative memory measure and a lower probability of cocaine-positive urine at study exit, whereas a smaller trial in nontreatment-seeking cocaine-dependent volunteers found no effect on craving or total use. A separate fMRI study suggests possible dose-related modulation of appetite ratings and cortico-limbic responses to high-calorie food cues, without short-term weight change.
Key areas needing more research include larger, well-powered randomized controlled trials with standardized dosing, longer follow-up, and harmonized outcome measures to clarify the magnitude and durability of cognitive effects and to determine whether benefits generalize beyond select subgroups (e.g., “inefficient memory” older adults). In glaucoma, confirmatory trials that link electrophysiologic improvements to clinically meaningful visual outcomes (e.g., visual field progression) and that rigorously evaluate long-term safety and treatment schedules (including washout effects) are warranted. In substance use disorders, the discrepant findings across populations and endpoints indicate a need to identify moderators (e.g., comorbid psychiatric illness, treatment-seeking status, baseline use severity), to separate effects on cognition from effects on drug use, and to test whether citicoline has clinically relevant benefits as an adjunct to behavioral therapies. Mechanistic work (e.g., biomarkers of cholinergic/dopaminergic function, neuroimaging correlates) could help explain heterogeneity and guide dose selection.
1. What conditions has Citicoline been studied for?
Glaucoma (moderate visual defects): Studied for effects on retinal function and neural conduction in visual pathways using objective electrophysiology (pattern electroretinogram; visual evoked potentials), including long-term follow-up.
Bipolar disorder with cocaine dependence: Studied as an add-on treatment to assess cognition (memory), mood symptoms, and cocaine use.
Cocaine dependence (non-treatment-seeking volunteers): Studied for effects on craving and cocaine use during an 8-week treatment period plus follow-up.
Appetite/food craving and brain responses to food cues: Studied using appetite ratings, weight, and fMRI responses to high-calorie food images (500 mg/day vs 2,000 mg/day).
Age-related memory deficits (older adults without dementia): Studied for memory performance improvements at doses ranging from ~300–2,000 mg/day, including placebo-controlled and crossover designs.
2. Does it work in treating those conditions? Summarize the evidence.
-
Glaucoma-related visual dysfunction: Suggestive benefit (objective measures), treatment-dependent.
After two 60-day periods of oral (1600 mg/day) or intramuscular (1000 mg/day) citicoline, patients showed improved retinal function (pattern ERG) and improved neural conduction (VEP).
Improvements partially regressed after washout (two 120-day washout periods), implying effects were at least partly dependent on ongoing treatment.
Long-term extension “up to 8 years” was associated with stabilization or improvement of glaucomatous visual dysfunction (suggestive, but details like control group and design are not provided in the abstract).
-
Bipolar disorder with cocaine dependence: Mixed results—memory and cocaine-use signal, no mood benefit.
In a 12-week randomized, placebo-controlled add-on trial (n=44), citicoline showed a significant advantage on a declarative memory measure (Rey Auditory Verbal Learning Test alternative word list; P=0.006).
No significant between-group differences were found for depressive symptoms (Inventory of Depressive Symptomatology-Self-Report) or mania symptoms (Young Mania Rating Scale).
Cocaine use: citicoline group had a lower probability of cocaine-positive urine at exit (P=0.026); adjusted odds ratio estimate suggested placebo participants had 6.41× higher odds of testing positive at exit.
-
Cocaine dependence (heavy users, non-treatment-seeking): No clear efficacy for craving or total use in a small trial.
In an 8-week double-blind placebo-controlled study (29 randomized; 18 completed), citicoline 500 mg twice daily had no effect on cocaine craving or total use.
This negative finding is limited by small sample size and the population being non-treatment-seeking.
-
Appetite modulation: Preliminary dose-related signal, unclear clinical impact.
Over 6 weeks, 2,000 mg/day (but not 500 mg/day) was associated with significant declines in appetite ratings.
No significant change in weight status was observed.
fMRI showed increased responses to high-calorie food images in amygdala, insula, and lateral orbitofrontal cortex in the higher-dose group; these changes correlated with appetite rating declines (mechanistic signal, not proof of clinical benefit).
-
Age-related memory deficits (without dementia): Evidence of improved verbal/free recall, especially in those with poorer baseline memory.
In elderly subjects with memory deficits (N=24), 4 weeks of citicoline (500–1000 mg/day) or citicoline + nimodipine improved free recall measures (word recall, immediate and delayed object recall) versus placebo, but not recognition tests.
In older volunteers (50–85), a 3-month parallel-group study found improved delayed recall only in those with relatively inefficient memories.
In a crossover study of that subgroup, 2,000 mg/day for 2 months was “clearly associated” with improved immediate and delayed logical memory.
3. What health benefits does it have?
-
Cognitive benefits (most consistent across abstracts):
Improved aspects of verbal memory in older adults with relatively inefficient memory (immediate and delayed logical memory at 2,000 mg/day; delayed recall benefit in a subgroup at 1,000 mg/day).
Improved free recall tasks in elderly subjects with memory deficits (300–1000 mg/day range reported; recognition not improved).
Improved performance on a declarative memory measure in bipolar disorder with cocaine dependence (Rey Auditory Verbal Learning Test alternative word list).
-
Visual pathway/retinal function in glaucoma (objective electrophysiology):
Improvements in pattern ERG and VEP after 60-day treatment cycles; partial regression after washout suggests an ongoing-treatment component.
Long-term treatment extension reported stabilization/improvement up to 8 years (suggestive neuroprotective effect, but details are limited in the abstract).
-
Potential substance-use related benefit (in one trial):
Lower probability of cocaine-positive urine at trial exit in bipolar disorder with cocaine dependence (12-week RCT), though another small trial in heavy users found no effect on craving or total use.
-
Potential appetite modulation at higher dose (preliminary):
Reduced appetite ratings at 2,000 mg/day over 6 weeks, without weight change; accompanied by fMRI changes correlated with appetite reductions.
4. Does it have any downsides or side effects?
-
Generally well tolerated in the cited trials, with limited adverse-event detail in the abstracts.
In the 12-week bipolar + cocaine dependence trial, citicoline was reported as well tolerated, with no participants discontinuing due to medication side effects (as far as the authors knew).
-
Physiologic changes reported in older adults:
In elderly subjects with memory deficits, citicoline was associated with a decrease in systolic blood pressure and minor changes in lymphocyte cell counting. The abstract frames these as consistent with “vasoregulatory and neuroimmune actions,” but they may be relevant for people with hypotension risk or immune-related concerns.
-
Limitations/uncertainties:
Several studies are small (e.g., N=24; 29 randomized with 18 completers; imaging study over 6 weeks), and abstracts often do not provide comprehensive adverse-event tables, so uncommon side effects cannot be ruled out from these summaries alone.
In glaucoma, benefits partially regressed after washout, implying that stopping may reduce gains (not a “side effect,” but relevant to expectations and long-term management).
5. Is it beneficial or harmful for any genetic variations (pharmacogenomics)?
The provided abstracts do not report analyses by genotype, do not identify pharmacogenomic subgroups, and do not link citicoline response or adverse effects to specific genetic variants. Based on these abstracts alone, there is insufficient evidence to conclude that citicoline is beneficial or harmful for any particular genetic variation.
References
-
Evidence of the neuroprotective role of citicoline in glaucoma patients
Vincenzo Parisi, Giovanni Coppola, Marco Centofanti, Francesco Oddone, Anna Maria Angrisani (2008) -
A randomized, placebo-controlled trial of citicoline add-on therapy in outpatients with bipolar disorder and cocaine dependence
E Sherwood Brown, April R Gorman, Linda S Hynan (2007) -
Effects of daily treatment with citicoline: a double-blind, placebo-controlled study in cocaine-dependent volunteers
Stephanie C Licata, David M Penetar, Caitlin Ravichandran, John Rodolico, Christopher Palmer (2011) -
Citicoline affects appetite and cortico-limbic responses to images of high-calorie foods
William D S Killgore, Amy J Ross, Toshikazu Kamiya, Yoko Kawada, Perry F Renshaw (2010) -
Citicoline improves memory performance in elderly subjects
X A Alvarez, M Laredo, D Corzo, L Fernández-Novoa, R Mouzo (1997) -
Citicoline improves verbal memory in aging
P A Spiers, D Myers, G S Hochanadel, H R Lieberman, R J Wurtman (1996)
Upload Whole Genome Sequencing (WGS) raw DNA data today!
Or upload raw DNA data to get started with your free analysis!